Clinical trial
Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly…
NCT00046930 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00046930 |
|---|---|
| Title | Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia |
| Official title | A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia… |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH Eli Lilly and Company Industry Kanisa Pharmaceuticals |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride, zosuquidar trihydrochloride, Placebo |
| Enrollment | 449 |
| Start date | Sep 17, 2002 |
| Primary completion | Jun 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 5, 2023 |
| Countries | Israel, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: